Is Alto Neuroscience, Inc. (ANRO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.6% / 30% | 26.1% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 2.6% / 33% | 26.1% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 9.5% / 33% | 94.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 2.6% / 33% | 26.1% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 9.5% / 33% | 94.8% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -41.8% | |
| Return on Assets (ROA) | -22.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$47M |
| Free Cash Flow | -$49M |
| Total Debt | $17M |
| Debt-to-Equity | 15.9 |
| Current Ratio | 15.7 |
| Total Assets | $178M |
Price & Trading
| Last Close | $20.82 |
| 50-Day MA | $18.82 |
| 200-Day MA | $10.68 |
| Avg Volume | 238K |
| Beta | 2.6 |
|
52-Week Range
$1.60
| |
About Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Alto Neuroscience, Inc. (ANRO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Alto Neuroscience, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Alto Neuroscience, Inc.'s debt ratio?
Alto Neuroscience, Inc.'s debt ratio is 2.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 9.5%.
What are Alto Neuroscience, Inc.'s key financial metrics?
Alto Neuroscience, Inc. has a market capitalization of $655M. Return on equity stands at -41.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.